Effect of the levonorgestrel intrauterine device on genital HIV-1 RNA shedding among HIV-1-infected women not taking antiretroviral therapy in Nairobi, Kenya

J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):245-8. doi: 10.1097/QAI.0b013e31828decf8.


The effect of the levonorgestrel-releasing intrauterine device (LNG-IUD) on genital HIV-1 RNA shedding and inflammation among 25 HIV-infected women was evaluated. Blood, endocervical, and cervicovaginal lavage samples were collected from HIV-infected women not taking antiretrovirals before LNG-IUD insertion and 1 month, 3 month, and 6 months thereafter. HIV-1 RNA was quantitated by real-time reverse transcriptase-polymerase chain reaction. Inflammatory markers were measured by enzyme immunoassay. Genital HIV-1 RNA shedding and inflammatory markers did not differ between LNG-IUD placement and month 6, with the exception of interleukin 1β that increased (0.42 log10; 95% confidence interval: 0.10 to 0.75). The LNG-IUD did not increase genital HIV-1 RNA shedding after 6 months of use.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Retroviral Agents / therapeutic use
  • CD4 Lymphocyte Count
  • Cervix Uteri
  • Contraceptive Agents, Female / therapeutic use
  • Female
  • HIV Infections
  • HIV-1 / drug effects
  • HIV-1 / genetics
  • Humans
  • Interleukin-1beta / blood
  • Intrauterine Devices, Medicated*
  • Kenya
  • Levonorgestrel / therapeutic use*
  • RNA, Viral / analysis*
  • RNA, Viral / blood*
  • Vaginal Douching


  • Anti-Retroviral Agents
  • Contraceptive Agents, Female
  • Interleukin-1beta
  • RNA, Viral
  • Levonorgestrel